M Brampton

1.0k total citations
8 papers, 785 citations indexed

About

M Brampton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M Brampton has authored 8 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in M Brampton's work include Lung Cancer Research Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Melanoma and MAPK Pathways (2 papers). M Brampton is often cited by papers focused on Lung Cancer Research Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Melanoma and MAPK Pathways (2 papers). M Brampton collaborates with scholars based in United Kingdom, Australia and United States. M Brampton's co-authors include E.S. Newlands, M. F. G. STEVENS, J. Margison, D. Ferry, Valery Yu. Alakhov, David J. Kerr, Sarah Danson, Malcolm Ranson, Gavin Halbert and A. Hilary Calvert and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

M Brampton

7 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Brampton United Kingdom	6	329	250	227	199	181	8	785
F. B. Oldham United States	15	270 0.8×	397 1.6×	253 1.1×	112 0.6×	116 0.6×	31	939
Margaret Tonda United States	16	339 1.0×	370 1.5×	358 1.6×	282 1.4×	102 0.6×	45	1.3k
Kenneth D. Bagshawe United Kingdom	21	570 1.7×	266 1.1×	83 0.4×	97 0.5×	89 0.5×	44	1.3k
Seock Ah Im South Korea	9	320 1.0×	288 1.2×	330 1.5×	53 0.3×	80 0.4×	23	806
Robert S. Greenfield United States	17	480 1.5×	334 1.3×	215 0.9×	60 0.3×	53 0.3×	43	1.3k
H. Sinn Germany	14	237 0.7×	125 0.5×	131 0.6×	49 0.2×	143 0.8×	41	739
Hannsjörg Sinn Germany	10	322 1.0×	142 0.6×	182 0.8×	40 0.2×	91 0.5×	16	704
Karin Leotta Germany	17	383 1.2×	303 1.2×	82 0.4×	91 0.5×	575 3.2×	22	1.3k
Henrike Caysa Germany	13	211 0.6×	115 0.5×	225 1.0×	108 0.5×	35 0.2×	15	662
Agnieszka Morgenroth Germany	21	400 1.2×	293 1.2×	175 0.8×	47 0.2×	170 0.9×	56	991

Countries citing papers authored by M Brampton

Since Specialization

Citations

This map shows the geographic impact of M Brampton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Brampton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Brampton more than expected).

Fields of papers citing papers by M Brampton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Brampton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Brampton. The network helps show where M Brampton may publish in the future.

Co-authorship network of co-authors of M Brampton

This figure shows the co-authorship network connecting the top 25 collaborators of M Brampton. A scholar is included among the top collaborators of M Brampton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Brampton. M Brampton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Danson, Sarah, D. Ferry, Valery Yu. Alakhov, et al.. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. 90(11). 2085–2091. 298 indexed citations

2.

Estlin, EJ, CR Pinkerton, I J Lewis, et al.. (2001). A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children’s Cancer Study Group Investigation. British Journal of Cancer. 84(1). 11–18. 14 indexed citations

3.

Porter, David, Alan V. Boddy, H. Thomas, et al.. (1996). Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.. PubMed. 23(6 Suppl 13). 34–44. 12 indexed citations

4.

Bleehen, N. M., E.S. Newlands, Siow Ming Lee, et al.. (1995). Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.. Journal of Clinical Oncology. 13(4). 910–913. 220 indexed citations

5.

Ledermann, Jonathan A., L. Holden, ES Newlands, et al.. (1994). The long‐term outcome of patients who relapse after chemotherapy for non‐seminomatous germ cell tumours. British Journal of Urology. 74(2). 225–230. 7 indexed citations

6.

Bleehen, NM, A H Calvert, Siow Ming Lee, et al.. (1994). A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma. British Journal of Cancer. 70(4). 775–777.

7.

O'Reilly, S.M., E.S. Newlands, M Brampton, et al.. (1993). Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. European Journal of Cancer. 29(7). 940–942. 231 indexed citations

8.

Leaning, M.S., S Gallivan, E.S. Newlands, et al.. (1992). Computer system for assisting with clinical interpretation of tumour marker data.. BMJ. 305(6857). 804–807. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact